Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Dong-Ki Lee Ph.D. | CEO & Director | -- | -- | 1972 |
| Jin Kim Young | Director of Finance Dept. | -- | -- | -- |
| Ms. Young Hye Baek | Executive Director of Legal Affairs | -- | -- | -- |
| Ms. Shin Young Park Ph.D. | Executive Vice President of Development Dept. | -- | -- | -- |
OliX Pharmaceuticals, Inc
- Sector:
- Healthcare
- Industry: Biotechnology
Description
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Corporate Governance
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
OliX Pharmaceuticals, Inc Earnings Date
Recent Events
Recent Events Information Not Available